Author/Authors :
Hideo Tamai، نويسنده , , Osamu Katoh، نويسنده , , Shin Suzuki MD، نويسنده , , Kenshi Fujii، نويسنده , , Tadanori Aizawa، نويسنده , , Shinichi Takase، نويسنده , , Hiroyuki Kurogane، نويسنده , , Hideo Nishikawa، نويسنده , , Takahito Sone، نويسنده , , Kazuyoshi Sakai، نويسنده , , Takahiko Suzuki and For the Tranilast Restenosis Following Angioplasty Trial Study Group، نويسنده ,
Abstract :
Background: Tranilast is an antiallergic drug that suppresses the release of cytokines such as platelet-derived growth factor, transforming growth factor-β1, and interleukin-1β and prevents keloid formation after skin injury. Treatment with this drug reduced the restenosis rate after percutaneous transluminal coronary angioplasty in a preliminary study. Methods and Results: We conducted a multicenter, randomized, double-blind, placebo-controlled trial. A total of 255 patients with 289 lesions were randomly assigned to treatment with the oral administration of 600 mg/d tranilast, 300 mg/d tranilast, or a placebo for 3 months after successful angioplasty. Angiographic follow-up was done at 3 months, and a clinical follow-up examination was performed at 12 months. Two hundred ten (72.7%) lesions of 188 (73.7%) of the patients met the criteria and were eligible for the assessment of restenosis. The restenosis rates defined as ≥50% loss of the initial gain were 14.7% in the 600 mg/d tranilast group, 35.2% in the 300 mg/d tranilast group, and 46.5% in the placebo group (P < .0001 for 600 mg/d tranilast vs placebo). The restenosis rates defined as percent diameter stenosis of ≥50% at follow-up were 17.6% in the 600 mg/d tranilast group, 38.6% in the 300 mg/d tranilast group, and 39.4% in the placebo group (P = .005 for 600 mg/d tranilast vs placebo). Conclusions: The oral administration of 600 mg/d of tranilast for 3 months markedly reduced the restenosis rate after percutaneous transluminal coronary angioplasty. (Am Heart J 1999;138:968-75.)
